95209-84-0

Usage

Uses

Used in Organic Synthesis:
1(6H)-Pyridazineacetic acid, 6-oxo-(6CI,9CI) is used as a building block in organic synthesis for the creation of various chemical compounds. Its unique structure allows for the formation of new molecules with potential applications in different industries.
Used in Pharmaceutical Research:
1(6H)-Pyridazineacetic acid, 6-oxo-(6CI,9CI) is utilized in pharmaceutical research for the development of new drugs and pharmaceuticals. Its distinctive chemical structure and properties make it a promising candidate for the creation of innovative therapeutic agents.
Used in Drug Development:
Due to its potential applications in the development of new drugs and pharmaceuticals, 1(6H)-Pyridazineacetic acid, 6-oxo-(6CI,9CI) is employed in drug development processes. Researchers can leverage its unique characteristics to design and synthesize novel compounds with potential therapeutic benefits.

Upstream product

• 89581-61-3 2-[6-chloro-pyridazin-3(2H)-one-2-yl]-acetic acid 
• 874491-58-4 ethyl 2-(6-oxopyridazin-1(6H)-yl)acetate 
• 504-30-3 2H-Pyridazin-3-one 
• 79-11-8 chloroacetic acid 

Relevant academic research and scientific papers

Nitrogen heterocyclic ring group substituted amide derivative and application thereof

The invention discloses a nitrogen heterocyclic ring group substituted amide derivative and application thereof, particularly relates to a novel nitrogen heterocyclic ring group substituted amide derivative and a drug composition comprising the compound, and further relates to methods for preparing the compound and the drug composition, and application of the compound and the drug composition to preparation of drugs for treating diseases or symptoms, particularly overactive bladder, excited and mediated by beta 3-adrenergic receptors. The compound and the drug composition can be used for activating the beta 3-adrenergic receptors.

NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor. (I).

HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.